Login to Your Account


Astrazeneca rebuffs new $107.94B offer from Pfizer

By Nuala Moran
Staff Writer

Monday, May 5, 2014
LONDON – It took Astrazeneca plc just a little over three hours on Friday morning to reject an improved £50 (US$84.32) per share offer from Pfizer Inc., valuing the UK company at about £64 billion (US$107.94 billion), saying the terms are inadequate, substantially undervaluing Astrazeneca and are not a basis on which to engage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription